Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | CDC25A | P30304 | 1/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL28999740 | 1.00 | SLC22A1 (0.46) | SLC22A1LMNAESR1ADORA3CDC25A | |
| Tetrabuthylammonium SCHEMBL25270463 | 0.89 | SLC22A1 (0.46) | SLC22A1LMNAESR1ADORA3CDC25A | |
| Tetrabuthylammonium SCHEMBL49814 | 0.81 | SLC22A1 (0.71) | SLC22A1LMNAESR1ADORA3CDC25A | |
| Tetrabuthylammonium SCHEMBL19834900 | 0.81 | SLC22A1 (0.71) | SLC22A1LMNAESR1ADORA3CDC25A | |
| Tetrabuthylammonium SCHEMBL6283913 | 0.81 | SLC22A1 (0.46) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL25270462 | 0.81 | SMPD1 (0.50) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL703752 | 0.79 | SLC22A1 (0.67) | SLC22A1LMNAESR1ADORA3CDC25A | |
| Tetrabuthylammonium SCHEMBL31067882 | 0.79 | SLC22A1 (0.67) | SLC22A1LMNAESR1ADORA3CDC25A | |
| Tetrabuthylammonium SCHEMBL3141779 | 0.79 | SLC22A1 (0.67) | SLC22A1LMNAESR1ADORA3CDC25A | |
| Tetrabuthylammonium SCHEMBL28547695 | 0.79 | SLC22A1 (0.67) | SLC22A1LMNAESR1ADORA3CDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055373-A | Bridged tricyclic carbamoyl pyridone compounds and uses thereof | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4719608-A1 | QUINAZOLINYL-INDAZOLE DERIVATIVES AS THERAPEUTIC COMPOUNDS FOR HIV | GILEAD SCIENCES, INC. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCE INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12404262-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4594319-A1 | BICYCLIC COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250230296-A1 | POLYVINYLIDENE FLUORIDE RESIN COMPOSITION AND MOLDED BODY | KUREHA CORPORATION (JP) | 2025-07-17 | — | — | US | disclosed |
| EP-4566608-A2 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250179102-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-4440702-B1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-4445900-B1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| WO-2001052852-A1 | WATER SOLUBLE PRODRUGS OF AZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-07-26 | — | — | WO | disclosed |
| US-5959028-A | UNSATURATED CARBONYL COMPOUND AND ACTIVE METHYLENE GROUP COMPOUND, ASYMMETRIC MALONATE ESTER FOR PROTECTIVE COATINGS | NIPPON PAINT CO., LTD. (JP) | 1999-09-28 | — | — | US | disclosed |
| EP-0651023-B1 | Curable resin composition for coating uses | NIPPON PAINT CO LTD (JP) | 1999-07-14 | — | — | EP | disclosed |
| EP-0737725-B1 | Curable resin composition for coating use | NIPPON PAINT CO LTD (JP) | 1998-07-01 | — | — | EP | disclosed |
| US-5739230-A | CURABLE THROUGH A MICHAEL REACTION BETWEEN A COMPONENT HAVING A PLURALITY OF ALPHA,BETA-UNSATURATED CARBONYL GROUPS AND A COMPONENT HAVING A PLURALITY OF ACTIVATED METHYLENE GROUPS | NIPPON PAINT CO., LTD. (JP) | 1998-04-14 | — | — | US | disclosed |
| EP-0808860-A2 | Curable resin composition for coating use | NIPPON PAINT CO., LTD. (JP) | 1997-11-26 | — | — | EP | disclosed |
| EP-0737725-A1 | Curable resin composition for coating use | Nippon Paint Co., Ltd. (JP) | 1996-10-16 | — | — | EP | disclosed |
| US-5565525-A | CURABLE THROUGH MICHAEL REACTION | NIPPON PAINT CO., LTD. (JP) | 1996-10-15 | — | — | US | disclosed |
| EP-0651023-A2 | Curable resin composition for coating uses | Nippon Paint Co., Ltd. (JP) | 1995-05-03 | — | — | EP | disclosed |
| US-4678609-A | Process for the preparation of corticosteroid-21-phosphoric acids and their salts and the corticosteroid-21-phosphoric acid triesters | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179102-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | CD4, HAVCR2, MAVS | SLC22A1 2867/4885LMNA 3425/4885ESR1 2616/4885 |
| US-12404262-B2 | Therapeutic compounds for HIV virus infection | HAVCR2, MAVS, CD4 | SLC22A1 3351/4885LMNA 3518/4885ESR1 2647/4885 |
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | CCR10, CCR1, CCR3 | SLC22A1 2056/4885LMNA 3767/4885ESR1 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.